The Centenary Institute has collaborated with fellow medical research institute, the Hudson Institute in Victoria, to develop a novel model system for accurately monitoring tumour stage and immune cells involvement.
Head of Centenary’s Liver Enzymes in Metabolism and Inflammation Program, Professor Mark Gorrell, was involved in the research project.
Ovarian cancer develops slowly and the immune system is crucial in controlling the tumour. In this particular study, the researchers modified ovarian cancer cells so they glowed in a way that can be seen in live laboratory mice models – enabling counts of tumour cells and immune cell subsets when each tumour is removed.
This system has allowed the researchers to learn new information on tumour growth, as well as discover which immune cells are in the tumour.
The researchers plan to apply the model to other cancers, including liver cancer.
Professor John Rasko AO has led a world-first clinical trial into engineered stem cell treatment use, treating 15 patients with steroid resistant acute graft-versus-host disease.
Centenary Institute research has discovered that the lack of an enzyme in the liver called sphingosine kinase 2 results in pronounced insulin resistance and glucose intolerance, both symptoms of early stage type 2 diabetes.
Research led by the Centenary Institute has shown that a healthy weight and coffee consumption may help lower the risk of high-risk drinkers developing alcohol-induced cirrhosis.